EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel biomimetic nanoplasmonic sensor for rapid and accurate evaluation of checkpoint inhibitor immunotherapy

Razia Batool, Maria Soler, Rukmani Singh, Laura M Lechuga

Analytical and Bioanalytical Chemistry · 2024

DOI: 10.1007/s00216-024-05398-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical and Bioanalytical Chemistry, 2024. Verfasst von Razia Batool und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nanobiosensors and Bioanalytical Applications Group (NanoB2A), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST and CIBER-BBN, …. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Biosensing Techniques, Immunotherapy, Gold. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut Català de Nanociència i Nanotecnologia, Ministerio de Ciencia e Innovación, Consejo Superior de Investigaciones Cientificas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) emerged as promising immunotherapies for cancer treatment, harnessing the patient’s immune system to fight and eliminate tumor cells. However, despite their potential and proven efficacies, checkpoint inhibitors still face important challenges such as the tumor heterogeneity and resistance mechanisms, and the complex in vitro testing, which limits their widespread applicability and implementation to treat cancer. To address these challenges, we propose a novel analytical technique utilizing biomimetic label-free nanoplasmonic biosensors for rapid and reliable screening and evaluation of checkpoint inhibitors. We have designed and fabricated a low-density nanostructured plasmonic sensor based on gold nanodisks that enables the direct formation of a functional supported lipid bilayer, which acts as an artificial cell membrane for tumor ligand immobilization. With this biomimetic scaffold, our biosensing approach provides real-time, highly sensitive analysis of immune checkpoint pathways and direct assessment of the blocking effects of monoclonal antibodies in less than 20 min/test. We demonstrate the accuracy of our biomimetic sensor for the study of the programmed cell death protein 1 (PD1) checkpoint pathway, achieving a limit of detection of 6.7 ng/mL for direct PD1/PD-L1 interaction monitoring. Besides, we have performed dose–response inhibition curves for an anti-PD1 monoclonal antibody, obtaining a half maximal inhibitory concentration (IC 50 ) of 0.43 nM, within the same range than those obtained with conventional techniques. Our biomimetic sensor platform combines the potential of plasmonic technologies for rapid label-free analysis with the reliability of cell-based assay in terms of ligand mobility. The biosensor is integrated in a compact user-friendly device for the straightforward implementation in biomedical and pharmaceutical laboratories. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsBiosensing TechniquesImmunotherapyGoldBiomimeticsHumansLimit of DetectionBiomimetic MaterialsB7-H1 AntigenProgrammed Cell Death 1 ReceptorNanostructures

Stichwörter der Autor:innen

Artificial cell membraneCancer immunotherapyCheckpoint inhibitorsLabel-free analysisLocalized surface plasmon resonanceSensor biofunctionalization

Substanzen

Immune Checkpoint InhibitorsGoldB7-H1 AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Nanobiosensors and Bioanalytical Applications Group (NanoB2A), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST and CIBER-BBN, 08193, Bellaterra, Barcelona, Spain.
  • Nanobiosensors and Bioanalytical Applications Group (NanoB2A), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST and CIBER-BBN, 08193, Bellaterra, Barcelona, Spain. maria.soler@icn2.cat.
  • Nanobiosensors and Bioanalytical Applications Group (NanoB2A), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST and CIBER-BBN, 08193, Bellaterra, Barcelona, Spain. laura.lechuga@icn2.cat.

Förderung

  • Institut Català de Nanociència i Nanotecnologia
  • Ministerio de Ciencia e Innovación
  • Consejo Superior de Investigaciones Cientificas

Zitieren

APA

Batool, R., Soler, M., Singh, R., & Lechuga, L. M. (2024). A novel biomimetic nanoplasmonic sensor for rapid and accurate evaluation of checkpoint inhibitor immunotherapy. Analytical and Bioanalytical Chemistry. https://doi.org/10.1007/s00216-024-05398-3

Vancouver

Batool R, Soler M, Singh R, Lechuga LM. A novel biomimetic nanoplasmonic sensor for rapid and accurate evaluation of checkpoint inhibitor immunotherapy. Analytical and Bioanalytical Chemistry. 2024. doi:10.1007/s00216-024-05398-3

BibTeX
@article{Batool2024,
  author = {Batool, Razia and Soler, Maria and Singh, Rukmani and Lechuga, Laura M},
  title = {A novel biomimetic nanoplasmonic sensor for rapid and accurate evaluation of checkpoint inhibitor immunotherapy},
  journal = {Analytical and Bioanalytical Chemistry},
  year = {2024},
  doi = {10.1007/s00216-024-05398-3}
}
Kostenlos starten →